XML 19 R11.htm IDEA: XBRL DOCUMENT
v3.25.3

Segment Reporting | 12 Months Ended
--- | ---
Jun. 30, 2025
Statements [Line Items] |
Segment Reporting | NOTE 4. SEGMENT REPORTING Identification of reportable operating segments Operating segments are reported in a manner consistent with internal reports which are reviewed and used by Management and the Board of Directors (who are identified as the Chief Operating Decision Makers (‘CODM’)). The Group operates in one operating segment, being Cancer Immunotherapy.
Operating segment information June 30, 2025 |  | Immunotherapy A$ |  |  | Unallocated A$ |  |  | Consolidated A$ |
Revenue |  |  |  |  |  |  |  |  |  |  |  |
License revenue |  |  | — |  |  |  | — |  |  |  | — |
Other income |  |  |  |  |  |  |  |  |  |  |  |
Research material sales |  |  | 59,709 |  |  |  | — |  |  |  | 59,709 |
Grant income |  |  | 4,974,823 |  |  |  | — |  |  |  | 4,974,823 |
Miscellaneous income |  |  | — |  |  |  | 390 |  |  |  | 390 |
Net change on fair value movement |  |  | — |  |  |  | 9,242 |  |  |  | 9,242 |
Interest income |  |  | — |  |  |  | 5,287,209 |  |  |  | 5,287,209 |
Total revenue and other income |  |  | 5,034,532 |  |  |  | 5,296,841 |  |  |  | 10,331,373 |
Result |  |  |  |  |  |  |  |  |  |  |  |
Segment Result |  |  | (65,020,504 | ) |  |  | 3,586,339 |  |  |  | (61,434,165 | )
Profit/(loss) before income tax expense |  |  | (65,020,504 | ) |  |  | 3,586,339 |  |  |  | (61,434,165 | )
Income tax expense |  |  | — |  |  |  | — |  |  |  | — |
Loss after income tax expense |  |  |  |  |  |  |  |  |  |  | (61,434,165 | )
Total segment assets |  |  | 156,983,434 |  |  |  | — |  |  |  | 156,983,434 |
Total segment liabilities |  |  | 13,348,071 |  |  |  | — |  |  |  | 13,348,071 |
Operating segment information June 30, 2024 |  | Immunotherapy A$ |  |  | Unallocated A$ |  |  | Consolidated A$ |
Revenue |  |  |  |  |  |  |  |  |  |  |  |
License revenue |  |  | — |  |  |  | — |  |  |  | — |
Other income |  |  |  |  |  |  |  |  |  |  |  |
Research material sales |  |  | 119,089 |  |  |  | — |  |  |  | 119,089 |
Grant income |  |  | 3,722,788 |  |  |  | — |  |  |  | 3,722,788 |
Net gain on fair value movement of warrants |  |  | — |  |  |  | — |  |  |  | — |
Net gain on foreign exchange |  |  | — |  |  |  | 113,458 |  |  |  | 113,458 |
Interest income |  |  | — |  |  |  | 3,882,757 |  |  |  | 3,882,757 |
Total revenue and other income |  |  | 3,841,877 |  |  |  | 3,996,215 |  |  |  | 7,838,092 |
Result |  |  |  |  |  |  |  |  |  |  |  |
Segment Result |  |  | (46,556,929 | ) |  |  | 3,840,304 |  |  |  | (42,716,625 | )
Profit/(loss) before income tax expense |  |  | (46,556,929 | ) |  |  | 3,840,304 |  |  |  | (42,716,625 | )
Income tax expense |  |  | — |  |  |  | — |  |  |  | — |
Loss after income tax expense |  |  |  |  |  |  |  |  |  |  | (42,716,625 | )
Total segment assets |  |  | 201,579,281 |  |  |  | — |  |  |  | 201,579,281 |
Total segment liabilities |  |  | 12,057,539 |  |  |  | — |  |  |  | 12,057,539 |
Operating segment information June 30, 2023 |  | Immunotherapy A$ |  |  | Unallocated A$ |  |  | Consolidated A$ |
Revenue |
License revenue |  |  | — |  |  |  | — |  |  |  | — |
Other income |  |  |  |  |  |  |  |  |  |  |  |
Research material sales |  |  | 191,721 |  |  |  | — |  |  |  | 191,721 |
Grant income |  |  | 3,314,001 |  |  |  | — |  |  |  | 3,314,001 |
Net gain on fair value movement of warrants |  |  | — |  |  |  | 131,896 |  |  |  | 131,896 |
Net gain on foreign exchange |  |  | — |  |  |  | 623,511 |  |  |  | 623,511 |
Interest income |  |  | — |  |  |  | 938,999 |  |  |  | 938,999 |
Total revenue and other income |  |  | 3,505,722 |  |  |  | 1,694,406 |  |  |  | 5,200,128 |
Result |  |  |  |  |  |  |  |  |  |  |  |
Segment Result |  |  | (41,431,305 | ) |  |  | 1,534,957 |  |  |  | (39,896,348 | )
Profit/(loss) before income tax expense |  |  | (41,431,305 | ) |  |  | 1,534,957 |  |  |  | (39,896,348 | )
Income tax expense |  |  | — |  |  |  | — |  |  |  | — |
Loss after income tax expense |  |  |  |  |  |  |  |  |  |  | (39,896,348 | )
Total segment assets |  |  | 147,448,990 |  |  |  | — |  |  |  | 147,448,990 |
Total segment liabilities |  |  | 10,979,601 |  |  |  | — |  |  |  | 10,979,601 |

X
- Definition The entire disclosure for operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2025-01-01 -Section Disclosure -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | immp_StatementsLineItems
Namespace Prefix: | immp_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration